AXSM

Axsome Therapeutics, Inc.

Healthcare · $9.5B market cap

We can't put a fair value on AXSM right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth2.9% a year✗

Sales growth53.6% a year✓

Free cash flow growth—?

Return on invested capital-59.2%✗

Follow AXSM

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

2 of the investors we track hold AXSM. In Q2 2026, 1 added. Who we track

Torray Funds

Torray Funds · as of Q2 2026

$3.7M

14,928 shares

Polen Capital Management

Polen Capital Management · as of Q2 2026

$1.1M

4,468 shares

Moves in Q2 2026

Added: Polen Capital Management

Insider activity

Since Sep 3, 2026: no open-market purchases, 1 sale worth $2.1M and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Jacobson Mark L.

Chief Operating Officer · 2026-09-03

Sold

$2.1M

Other filings

Jacobson Mark L.

Chief Operating Officer · 2026-09-03

Option exercise

$130K

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is…

Biotechnology